Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Status:
RECRUITING
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.
Phase:
PHASE2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Foundation Medicine Go-2 Lung Merck Sharp & Dohme LLC